Avantor Appoints New EVP & Chief Transformation Officer Amid Executive Transition

summarizeSummary

Avantor announced a key executive transition, appointing Ludovic Brellier as EVP of Bioscience & Medtech Products and Chief Transformation Officer, signaling a strategic focus on operational improvement and growth following recent financial challenges.

check_boxKey Events

• Executive Departure

  Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products, will transition to a new role and is expected to depart the company by December 31, 2026.

• New Executive Appointment

  Ludovic Brellier has been appointed Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026.

• Strategic Transformation Focus

  Mr. Brellier will lead the "Revival Management Office" to drive transformation initiatives across the enterprise, focusing on growing the BMP business and improving operational performance. This follows a year of significant net losses for the company.

auto_awesomeAnalysis

Avantor, Inc. is undergoing a significant leadership transition in its Bioscience & Medtech Products (BMP) segment, bringing in a new Executive Vice President who will also serve as Chief Transformation Officer. This strategic appointment, following a year of substantial net losses and declining sales, signals a proactive effort to improve operational performance and drive growth. The new officer's background in bioprocessing and business transformation from Danaher suggests a focused approach to the company's "Revival" initiatives.